Max Financial Services Ltd.
Banking · NSE
52-week range
₹1,249 – ₹1,893
From 52w high
-10.2%
RSI (14)
61.0
vs SMA 50 / 200
↑ 50 · ↑ 200
Max Financial Services (MFSL) is the holding company for Max Life Insurance, currently trading at ₹1,694 — up 31.3% over 1 year and above both its 50-DMA (₹1,649.7) and 200-DMA (₹1,636.0). Trailing PE of 398.6x is the highest in its reported peer group, with a forward PE of 122.9x; 5-year revenue has contracted 40.2% and no ROE data is available for the most recent period. A mean analyst rating of 1.25 across 25 analysts (1–5 scale, lower = more constructive) represents one of the more constructive sell-side positions in the peer set.
- ✓Price above both 50-DMA (₹1,649.7) and 200-DMA (₹1,636.0), with RSI at 59.8 (neutral), and 31.3% 1-year price appreciation against nearest resistance at ₹1,710.4–₹1,752.2.
- ✓FCF-positive in 4 of available historical years, suggesting the insurance holding company has generated positive free cash flow in the majority of periods tracked.
- ✓Shareholder approval obtained for capital hike, fundraising, and the Axis Bank deal (per 2026-05-10 headline), indicating corporate actions to potentially strengthen the balance sheet or expand the joint venture.
- ✓Mean analyst rating of 1.25 across 25 analysts (1–5 scale, lower = more constructive) is the most constructive in the 6-peer group where analyst data is available.
- ✗Trailing PE of 398.6x is the highest among 6 reported peers — next highest is HDFCLIFE at 69.6x — indicating that current market price embeds an exceptionally large implied earnings recovery relative to current trailing earnings.
- ✗5-year revenue growth of -40.2% represents a significant multi-year contraction; at the same time, debtTrend is rising and D/E stands at 12.67, combining top-line pressure with increasing leverage.
- ✗Quality score of 27 and consistency score of 37 place MFSL in the lower tier of its peer group; ROE years above 15% is 0 in the available window, indicating no period of above-threshold capital returns in tracked history.
- ✗Q4 FY26 earnings call was first cancelled and then rescheduled within the same day (2026-05-10); cancellation of a pre-announced earnings call is an atypical disclosure event, and the reason for the initial cancellation is not specified in available news.
- ·Shareholders approved a capital hike, new fundraising, and the Axis Bank partnership structure (2026-05-10), which could alter the equity base, dilution profile, and insurance joint venture economics — specifics of the deal terms are not detailed in available headlines.
- ·Q4 FY26 earnings call was cancelled and then rescheduled for May 13, 2026; the company stated it reaffirmed disclosure commitments, but the sequence of events is unusual and the results have not yet been reported as of the run date.
- ·A new director was named for Axis Max Life (2026-05-07), reflecting ongoing governance changes at the insurance joint venture that Max Financial holds a majority stake in.
- ?Does the forward PE compression from 398.6x trailing to 122.9x forward reflect a genuine step-change in underwriting profitability at Max Life, or does it depend on one-off restructuring gains that may not recur?
- ?How does the 40.2% 5-year revenue contraction reconcile with the insurance sector growth trajectory — is this a function of MFSL reporting its holding company revenues differently post the Axis Bank partnership restructuring?
- ?What are the specific terms of the shareholder-approved capital hike and Axis Bank deal, and how will they affect MFSL's ownership percentage in Max Life Insurance and its reported consolidated financials?
- ?Given that ROE data is unavailable and the quality score ranks 4th of 6 in a peer group that includes both banks and an insurance peer, what is the appropriate benchmark for assessing MFSL's capital efficiency as a pure insurance holding company?
PE
398.6
Forward PE
122.9
ROE
—
Profit margin
+0.3%
D/E
12.67
Dividend yield
—
Quality score
27/100
ROE 5y above 15%
0/5 yrs
FCF 5y positive
4/5 yrs
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Market data sourced from public feeds; consult a registered adviser before any investment decision.Analysis generated 11 May 2026.